Preservation of native and living tissues, and methods for preservation and transport - Patents.com

The use of specially designed cassettes and a controlled cryoprotectant gradient with rapid cooling and warming processes addresses the low viability and inefficiencies in current cryopreservation methods, achieving high-throughput and improved tissue preservation.

JP2024544569AInactive Publication Date: 2024-12-03TISSUE TESTING TECHNOLOGIES LLC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024528616
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-15
Filing Date
2022-11-15
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current cryopreservation methods for bioengineered tissues result in low viability yields (typically less than 50%) and are not suitable for high-throughput processing, leading to inefficiencies in manufacturing and quality control.

Method used

A method involving specially designed cassettes and a stepwise cryoprotectant concentration gradient is used to preserve bioengineered tissues, with a final cryoprotectant concentration of up to 70% by weight, followed by rapid cooling and controlled warming to prevent ice crystal formation, allowing for high-throughput processing of multiple tissues simultaneously.

Benefits of technology

The method achieves significantly higher viability yields (greater than 50%) and enables efficient, high-throughput preservation of bioengineered tissues, reducing handling errors and improving product quality.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544569000001_ABST
    Figure 2024544569000001_ABST
Patent Text Reader

Abstract

Described herein are methods for preserving biological materials by vitrification while reducing or preventing the loss of viability associated with traditional preservation methods. Also described herein are cassettes and methods of using these cassettes for cryopreserving biological materials (e.g., bioengineered constructs or natural tissue samples).
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] [Government support] This invention was supported in whole or in part by grant 1R43TR003258-01 from the National Institutes of Health. The Government has certain rights in this invention.

[0002] [CROSS REFERENCE TO RELATED APPLICATIONS] This application claims priority to U.S. Provisional Application No. 63 / 279,237, filed November 15, 2021. The disclosure of the prior application is incorporated herein by reference in its entirety.

[0003] The present disclosure relates to methods for cryopreserving bioengineered tissues, such as natural tissues and bioengineered constructs, while reducing or preventing the loss of viability associated with traditional preservation methods. The disclosure further relates to specially designed cassettes and high throughput systems capable of preserving multiple natural tissues and bioengineered tissues, such as bioengineered constructs, at one time {e.g., by using specially designed cassettes that can hold a predetermined number (e.g., 6-384, e.g., 24) well inserts containing natural tissues and bioengineered tissues, such as bioengineered constructs, at one time}. [Background technology]

[0004] Over the past several decades, preservation methods and techniques have been developed for preserving eukaryotic tissues and cells. These preservation methods and techniques are directed to preserving a variety of eukaryotic cells in engineered extracellular matrices, engineered tissues, and natural tissues for periods of time in a manner that allows for the use of these preserved tissues at a later date, such as for implantation or transplantation into a patient, or for drug or chemical screening bioassays.

[0005] Although such preservation methods and techniques are widely applicable in both basic and translational research settings, maintaining biomaterial properties (e.g., cell viability and extracellular matrix integrity) during storage remains a challenge, especially for bioengineered constructs. For example, with current techniques, a significant decrease in extracellular matrix permeability and tissue cell viability has been observed, which may lead to inefficient functioning of biomaterials after removal from storage.

[0006] The development of in vitro assays for various human tissues answers the demand to reduce the number of animals used in research, to find more cost-effective ways to screen new drugs, compounds, or methods, and to find in vitro assays that are more predictive of in vivo responses in humans. A growing number of studies support the use of tissue engineered constructs made from various tissues, not just skin, for toxicity testing. In this regard, 3D human tissue models and tissue-equivalent constructs are replacing animal models in toxicity predictive screening and drug discovery models. These models are less costly and arguably closer to the natural human response than comparable animal models.

[0007] For example, companies involved in the manufacture of cosmetics, chemicals, household products, and pharmaceuticals have begun to use tissue equivalent constructs to replace animal testing (Afaq et al., Protective Effect of Pomegranate-Derived Products Against UVB-Mediated Damage in Reconstructed Human Skin, Exp Dermatol., 18(6):553-61 (2009); Felippi et al., Safety and Efficacy of Antioxidant-Containing Nanoparticles for Anti-Aging Applications, J Biomed Nanotechnol, 8(2):316-321 (2012); Jirova et al., Comparison of Human Skin Irritation Patch Test Data with In Vitro Skin Irritation Assays and Animal Data, Contact Dermatitis, 62(2):109-16 (2010); Kaluzhny et al., Development of the EpiOcular® Eye Irritation Test for Hazard Identification and Labeling of Eye Irritating Chemicals in Accordance with the Requirements of the EU Cosmetics Directive and REACH Legislation, Altern Lab Anim, 39(4):339-64 (2011);Non-Patent Document 5: Kolle et al., In-house validation of the EpiOcular® eye irritation test combined with the bovine corneal opacity and permeability test for the assessment of eye irritation, Altern Lab Anim, 39(4):365-87 (2011);Non-Patent Document 6: Ren et al., Use of EpiAirway for characterization of long-term host-pathogen interactions, J Vis Exp. 55: e3261 (2011);Non-Patent Document 7: Scheel et al., Classification and labeling of industrial products with extreme pH utilizing in vitro methods for evaluation of skin and eye irritation and corrosion using a weight of evidence approach, Toxicol In Vitro, 25(7):1435-47 (2011);Non-Patent Document 8: Sharma et al., Efficacy of Echinacea in a 3D tissue model of human airway epithelium, Phytother Res., 24(6):900-4(2010)). The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this disclosure pertains.

[0008] Due to European Union regulations banning the use of animals for collecting toxicological data on cosmetic ingredients since 2009, MatTek's in vitro tissue models, such as epidermis, have been validated for use in toxicity testing of cosmetic ingredients. It is expected that a ban on toxicity testing on animals will soon follow for other types of compounds, such as pharmaceuticals, increasing the demand for in vitro models of all tissue types. Tissue constructs are generally made from a single cell type, but with multiple cell layers. In some cases, constructs with multiple cell types have also been developed. As such, they are more complex than a monolayer of cells in a dish or plate, but quite different from native tissues, such as vein segments or cartilage pieces.

[0009] Such bioengineered human tissues are currently manufactured in custom batches by industrial suppliers and must be used immediately upon receipt. That is, bioengineered constructs are generally made to order, requiring several weeks of lead time for manufacturing prior to shipment. Shipments are sent overnight at 4°C, and bioengineered tissues, like bioengineered constructs, must be used within a finite period (1-2 weeks) for best results. Due to the short lifespan of such cellular material, quality control testing may not be completed prior to shipment and must be done after the fact. If the results of such quality control testing are delayed, it may become apparent that the batch did not meet the prescribed quality control standards after a customer has used the tissue equivalent in a research project and expended significant resources, time and effort. Availability may also be an issue when valid constructs become unavailable for a variety of reasons, including production issues due to weather or lack of suitable starting materials. Without this tool for toxicity testing, then, the development of drugs and other compounds would be put on hold, wasting time and money due to inactivity. Thus, there is a need for improved methodologies for preserving bioengineered tissues, such as bioengineered constructs, for later use.

[0010] Currently, cryopreservation is not used to preserve these tissues for later use. Cryopreservation would dramatically increase the availability of bioengineered tissues, such as bioengineered constructs, expand the market, and reduce overall manufacturing costs through economies of scale, resulting in more efficient shipping and delivery to customers.

[0011] That is, the method of cryopreserving bioengineered tissues, such as bioengineered constructs, eliminates the lead time required to manufacture bioengineered tissues to order, allows for quality control checks on inventory before shipping, and reduces costs through economies of scale. End users have more flexibility in scheduling experiments without worrying about the availability or quality of the bioengineered tissue. Customers can also order larger quantities of the same batch of product for better control of intra-study uniformity. Validated cryopreserved tissue constructs can be shipped to any laboratory in the food, pharmaceutical, cosmetic, and chemical industries and can be used as a convenient alternative to in vivo testing.

[0012] Although preservation of bioengineered tissues, like bioengineered constructs, seems straightforward at first glance, conventional cryopreservation by freezing does not yield viable bioengineered tissues, like bioengineered constructs (typically <50%).

[0013] The efficacy of vitrification strategies has been repeatedly demonstrated for preserving the structure, extracellular matrix, and viability of native and bioengineered tissues, ranging from blood vessels, heart valves, encapsulated cells, and cartilage (Brockbank et al., Quantitative Analysis of Vitrified Autologous Veno-Arterial Bypass Grafts, Cell Preservation Techniques, 5 (2) (2007); 68-76; Brockbank et al., Vitrification of Porcine Articular Cartilage, Cryobiology 60, 217-221, http: / / www.pubmedcentral.gov / articlerender.fcgi?artid=2834839 (2010); Dahl et al., Potential for Vitrification as a Preservation Method for Tissue Engineered Blood Vessels, Tissue Eng., 12(2):291-300 (2006); Schenke-Layland et al., Optimal Preservation of Extracellular Matrix in Cardiac Tissue: Implications for Long-Term Graft Durability, Annals of Thoracic Surgery, 83:1641-1650 (2007); Song et al., Vitreous cryopreservation to maintain the function of artificial blood vessels, Nature Biotechnology, 8(3):296-9, Epub 2000 / 03 / 04, doi:10.1038 / 73737, PubMed PMID: 10700144 (2000); Song et al., Vitrification of tissue engineered pancreatic substitutes, Transplantation Proceedings, 37 (1):253-255 (2005); and Song et al., Vitreous preservation of rabbit articular cartilage, Cell Preservation Technology, 2 (1); 67-74 (2004). The disclosures of these publications are hereby incorporated by reference in their entireties in order to more fully describe the state of the art to which this disclosure pertains. Vitrification is the solidification of a liquid without crystallization. As cooling proceeds, the molecular motion of the liquid through the tissue decreases. Eventually, a "liquid-in-stasis" state known as glass is achieved. It is this transformation of liquid to glass that is called vitrification (from the Greek "vitri" meaning glass).Vitrification can be achieved by tailoring the solute composition and cooling rate to prevent the nucleation and growth of ice crystals. [Prior art documents] [Non-patent literature]

[0014] [Non-Patent Document 1] Afaq et al., Protective effect of pomegranate-derived products on UVB-mediated damage in human reconstituted skin, Exp Dermatol., 18(6): 553-61 (2009) [Non-Patent Document 2] Felippi et al., Safety and efficacy of antioxidants-loaded nanoparticles for an anti-aging application, J Biomed Nanotechnol, 8(2): 316- 321 (2012) [Non-Patent Document 3] Jirova et al., Comparison of human skin irritation patch test data with in vitro skin irritation assays and animal data, Contact Dermatitis, 62(2): 109-16 (2010) [Non-Patent Document 4] Kaluzhny et al., Development of the EpiOcular(TM)eye irritation test for hazard identification and labeling of eye irritating chemicals in response to the requirements of the EU cosmetics directive and REACH legislation, Altern Lab Anim, 39(4): 339-64 (2011) [Non-Patent Document 5] Kolle et al., In-house validation of the EpiOcular(TM)eye irritation test and its combination with the bovine corneal opacity and permeability test for the assessment of ocular irritation, Altern Lab Anim, 39(4): 365-87 (2011) [Non-Patent Document 6] Ren et al., Use of the EpiAirway model for characterizing long-term host-pathogen interactions. J Vis Exp. 55: e3261 (2011) [Non-Patent Document 7] Scheel et al., Classification and labeling of industrial products with extreme pH by making use of in vitro methods for the assessment of skin and eye irritation and corrosion in a weight of evidence approach, Toxicol In Vitro, 25(7): 1435-47 (2011) [Non-Patent Document 8] Sharma et al., The efficacy of Ehcinacea in a 3-D tissue model of human airway epithelium, Phytother Res., 24(6): 900-4 (2010) [Non-Patent Document 9] Brockbank et al., Quantitative Analyses of Vitrified Autologous Venous Arterial Bypass Graft Explants, Cell Preservation Technology, 5 (2) (2007); 68-76 [Non-Patent Document 10] Brockbank et al., Vitrification of Porcine Articular Cartilage, Cryobiology 60, 217-221, http: / / www.pubmedcentral.gov / articlerender.fcgi?artid=2834839 (2010) [Non-Patent Document 11] Dahl et al., Feasibility of vitrification as a storage method for tissue-engineered blood vessels, Tissue Eng., 12(2):291-300 (2006) [Non-Patent Document 12] Schenke-Layland et al., Optimized preservation of extracellular matrix in cardiac tissues: implications for long-term graft durability, Annals of Thoracic Surgery, 83:1641-1650 (2007) [Non-Patent Document 13] Song et al., Vitreous cryopreservation maintains the function of vascular grafts, Nature Biotechnology, 8(3):296-9, Epub 2000 / 03 / 04, doi:10.1038 / 73737, PubMed PMID: 10700144 (2000) [Non-Patent Document 14] Song et al., Vitrification of tissue engineered pancreatic substitute, Transplantation Proceedings, 37 (1):253-255 (2005) [Non-Patent Document 15] Song et al., Vitreous Preservation of Rabbit Articular Cartilage, Cell Preservation Technology, 2 (1); 67-74 (2004) Summary of the Invention [Problem to be solved by the invention]

[0015] However, a drawback of using high concentrations of cryoprotectants (CPAs) commonly used in the vitrification process is potential cytotoxicity.However, one advantage of vitrification is that biological material trapped within the vitreous matrix does not degrade over time, so there is no biological damage associated with freezing.

[0016] Thus, while cryopreservation of individual constructs has been successful, there is a need to improve the yield of viable tissue constructs (i.e., significantly higher than 50%). Additionally, while it is possible to preserve multiple constructs at once (previously only possible with two technicians working together), there is still a need for high throughput systems that can preserve multiple constructs at once and have a yield of viable tissue constructs significantly higher than 50%.

[0017] The inventors of the present disclosure have developed a methodology that allows this to be accomplished (i.e., preservation of individual natural or bioengineered tissues, such as bioengineered constructs, or multiple natural and / or bioengineered tissues, e.g., bioengineered constructs, with a yield of viable tissue constructs significantly higher than 50%). In some embodiments, this involves using a cassette of the present disclosure that can hold and successfully store a large number (e.g., 24 or up to 384) of well inserts at a time, including natural tissues and / or bioengineered constructs, such as bioengineered constructs. The cassette has two parts that fit together to hold the inserts. At the top, there is a placeholder to hold the inserts in an arrangement that matches the well arrangement of the well plate. This configuration allows easy transfer of biomaterials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) from the cassette to the plate as needed. Holes are present in both parts of the cassette, allowing solutions (such as those used during the vitrification step) to easily flow through and around each insert and biomaterial (e.g., native and / or bioengineered tissues such as bioengineered constructs). In some embodiments, the cassette can be immersed in vitrification solution during the cryoprotectant injection / removal steps and the actual vitrification. The placeholder can be easily modified to hold fragments of native tissue for preservation as well. This cassette can be easily adapted for automation of the entire vitrification process. [Means for solving the problem]

[0018] Described herein are methods for preserving biological materials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) while reducing or preventing the loss of viability associated with conventional preservation methods. Also described herein are cassettes and methods of using these cassettes for cryopreserving biological materials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs).

[0019] In this regard, described herein is a method for preserving at least one bioengineered construct or natural tissue sample, comprising the steps of: (i) immersing said at least one bioengineered construct or natural tissue sample in a series of solutions with increasing concentrations of a cryoprotectant to form at least one first bioengineered construct or natural tissue immersed in a final solution having a cryoprotectant concentration less than or equal to 70% by weight; (ii) preserving said at least one first bioengineered construct or natural tissue in said final solution having a cryoprotectant concentration less than or equal to 70% by weight; % or less, and (iii) immersing the at least one first bioengineered construct or natural tissue in a series of solutions with decreasing concentrations of the cryoprotectant to obtain at least one second bioengineered construct or natural tissue immersed in a solution substantially free of cryoprotectant, wherein the at least one second bioengineered construct or natural tissue is substantially free of cryoprotectant. [Brief description of the drawings]

[0020] [Figure 1] 1 shows a schematic diagram of a cassette according to an embodiment. [Figure 2A] FIG. 13 is a schematic diagram showing an embodiment of a cassette taken together and illustrating how the biomaterial fits into the cassette. [Figure 2B] FIG. 2B shows a side view of the cassette of FIG. 2A in a closed position. [Figure 2C] FIG. 2C shows a side view of the cassette of FIG. 2B with the lid removed. [Figure 2D] FIG. 2C shows a side view of the cassette of FIG. 2B with two sides of the cassette with a biological material sample disposed on one side. [Figure 2E] 2E shows a side view of both sides of the cassette of FIG. 2D. [Diagram 3] 1 is a photograph of a cassette according to an embodiment. [Figure 4] 1 is a chart showing the viability of epidermal constructs following protocol modifications according to disclosed embodiments. [Diagram 5] FIG. 5 is a chart showing the viability of fresh and vitrified epidermis following exposure to Triton-X100, according to disclosed embodiments. [Figure 6] FIG. 6 is a chart illustrating the viability of several constructs after vitrification in vials and deep well plates, according to disclosed embodiments. [Figure 7] FIG. 7 is a chart illustrating the post-storage viability of various constructs, according to disclosed embodiments. [Figure 8] FIG. 8 is a chart illustrating viability in deep well plates and cassettes according to disclosed embodiments. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0021] The disclosed cassettes and methods may be understood more readily by reference to the following detailed description of specific embodiments, the examples contained herein, and the figures and their descriptions.

[0022] In this specification and in the claims that follow, reference will be made to a number of terms that shall be defined to have the following meanings.

[0023] As used herein, the term "room temperature" refers to a temperature at standard pressure of about 18° C. to about 25° C. In various examples, room temperature can be about 18° C., about 19° C., about 20° C., about 21° C., about 22° C., about 23° C., about 24° C., or about 25° C.

[0024] As used herein, the term "vitrification" refers to solidification without or without substantial ice crystal formation. In some embodiments, the sample to be stored (e.g., tissue or cellular material, etc.) can be vitrified such that vitrification and / or vitreous cryopreservation (from initial cooling to completion of rewarming) can be achieved without ice crystal formation. In some embodiments, the sample to be stored (e.g., tissue or cellular material, etc.) can be vitrified such that vitrification and / or vitreous cryopreservation can be achieved in which solidification of the sample to be stored (e.g., tissue or cellular material, etc.) can occur without substantial ice crystal formation (i.e., vitrification and / or vitreous cryopreservation (from initial cooling to completion of rewarming) can be achieved in the presence of a small or limited amount of ice that is less than the amount that would damage the tissue).

[0025] As used herein, a sample or biological material to be preserved (e.g., a natural tissue or a bioengineered tissue, such as a bioengineered construct) is vitrified when it reaches its glass transition temperature (Tg). During vitrification, the viscosity of the cryoprotectant solution increases significantly as the temperature is decreased, inhibiting ice nucleation and growth. In general, the lowest temperature that a solution can be supercooled without freezing is known as the homogeneous nucleation temperature, T h is the temperature at which ice crystals nucleate and grow, forming a crystalline solid from the solution. Vitrified solutions have a glass transition temperature, T g At this temperature the solute vitrifies, that is, becomes a non-crystalline solid.

[0026] As used herein, "glass transition temperature" refers to the glass transition temperature of a solution or formulation under the conditions in which the process is carried out. In general, the methodology of the present disclosure is carried out at physiological pressure. However, higher pressures can be used as long as the sample to be preserved (e.g., tissue or cellular material, etc.) is not significantly damaged thereby.

[0027] As used herein, the term "cryoprotectant" refers to a chemical that minimizes ice crystal formation in and around tissues / organs when the tissues are cooled to below freezing, and causes substantially no damage to the tissues / organs after warming compared to the effects of cooling without a cryoprotectant.

[0028] As used herein, the term "biomaterial" includes natural and / or bioengineered cells or tissues, or bioengineered constructs of non-plant, mammalian eukaryotic organisms. As used herein, the terms "tissue", "tissues", "construct" or "constructs" refer to any type of cell type and / or any combination thereof, such as ovarian tissue, testicular tissue, umbilical cord tissue, placental tissue, connective tissue, cardiac tissue, muscle, cartilage and bone tissue, endocrine tissue, skin, nervous tissue, somatic cells (including any type of cell within a tissue or organ), fibroblasts, keratinocytes, hepatocytes, chondrocytes, smooth muscle cells, stem cells, progenitor cells, oocytes, germ cells, etc.

[0029] The terms "tissue", "tissues", "construct" or "constructs" may also include adipose tissue or dental pulp tissue. In some embodiments, the "tissue" or "tissues" may be obtained from a human, such as human liver, human lung, human kidney, human intestine, human heart, human pancreas, human testis, human placenta, human thymus, human adrenal gland, human artery, human vein, human nerve, human skin, human lymph node, human bone or human skeletal muscle. In some embodiments, the "construct" or "constructs" may be obtained and / or derived from a human tissue or organ, such as human liver, human lung, human kidney, human intestine, human heart, human pancreas, human testis, human placenta, human thymus, human adrenal gland, human artery, human vein, human nerve, human skin, human lymph node, human bone or human skeletal muscle.

[0030] As used herein, the term "functional after cryopreservation" in relation to cryopreserved biomaterials means that cryopreserved biomaterials, such as natural and / or bioengineered cells and tissues, e.g., bioengineered constructs, retain acceptable and / or intended functions after cryopreservation (e.g., such as may serve as models for predictive toxicity screening and models for drug discovery). In some embodiments, the cellular material of the biomaterial after cryopreservation retains all of its intended functions. In some embodiments, the cellular cryopreserved biomaterials preserved by the methods of the present disclosure retain at least 50% of the intended function, e.g., at least 60% of the intended function, e.g., at least 70% of the intended function, e.g., at least 80% of the intended function, e.g., at least 90% of the intended function, e.g., at least 95% of the intended function, e.g., 100% of the intended function, etc. For example, along with maintaining cell viability, it may also be important to maintain / preserve the physiological function(s) of the biomaterial (e.g., natural tissue and / or bioengineered tissue such as a bioengineered construct) to serve as a model for predictive toxicity screening and drug discovery, and / or the ability of the tissue (e.g., to be implanted) to integrate with surrounding tissues.

[0031] Described herein are viable biological materials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) and methods for preserving / storing such constructs, such as within the cassettes of the present disclosure.

[0032] In certain aspects, these biomaterials include eukaryotic cells (which may be either engineered or natural tissues, or a combination of both), and the methods described herein include preserving / storing these biomaterial(s) (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues) in a manner that reduces or prevents loss of biomaterial properties (e.g., tissue / cell viability, extracellular matrix integrity, or a combination thereof) that occurs either during storage or after removal of the biomaterials (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues) from storage. In embodiments, these biomaterials (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues) are placed into a solution or series of solutions (e.g., to achieve a final cryoprotectant concentration), such as pre-cooled vitrification solution(s), that includes at least one agent, such as a cryoprotectant. The biomaterials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) placed in a solution containing at least one agent are then stored at a specific temperature range until the biomaterials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) are further required. The concentration of the at least one agent, such as a cryoprotectant, is optimized to maximize the biomaterial properties (e.g., cell viability and / or extracellular matrix integrity) of the biomaterials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs).

[0033] When using the biomaterial(s) described herein (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) with the compositions and methods described herein, one objective is to prevent loss of cell viability and / or prevent loss of extracellular matrix integrity.

[0034] For example, in certain embodiments, the purpose of the present disclosure is to reduce or prevent the loss of cell viability of biomaterials.In certain embodiments, the compositions, cassettes and methods described herein can be used to reduce or prevent various types of cell death, including but not limited to necrotic cell death, apoptotic cell death, autophagy (type II) cell death, anoikis, and necroptosis, and in certain embodiments, these types of cell death can be limited by the use of agents as further described below.Metabolic activity assays (e.g., resazurin assay, which is used to evaluate cell viability by measuring the oxidation / reduction reactions occurring in cells), various cell staining techniques (e.g., trypan blue exclusion assay and live / dead staining), immunohistochemistry, biochemistry, and various gene expression assays can be used to evaluate viability.

[0035] Furthermore, the integrity of the extracellular matrix can be determined based on permeability, water content, glycosaminoglycan content, or a combination thereof. In certain embodiments, one objective is to maintain at least one of permeability, water content, glycosaminoglycan content, or a combination thereof during storage of biomaterial(s) to prevent or reduce the loss of extracellular matrix integrity. When determining the matrix integrity of biomaterial(s), a number of techniques known in the art can be used. These techniques include matrix electrical conductivity assays that measure permeability, water content, glycosaminoglycan content, indentation testing, stress / strain testing, elasticity, RAMAN spectroscopy, various microscopy methods (such as laser scanning microscopy with second harmonic generation), and the like.

[0036] In certain aspects, when tissue matrices are used as biomaterials, preventing or reducing the loss of cell viability and the integrity of the extracellular matrix is ​​important to maintain the structural integrity and normal biological function of the biomaterial.

[0037] For example, cartilage (e.g., either natural cartilage or bioengineered cartilage, such as bioengineered cartilage constructs) comprises chondrocytes (i.e., cells) and an extracellular matrix, the extracellular matrix being composed primarily of collagen fibers, proteoglycans, and elastin fibers. The viability of chondrocytes and the integrity of the cartilage extracellular matrix are important for maintaining normal physiological biological functions in in vivo, ex vivo, and in vitro applications. For example, the extracellular matrix of cartilage provides structural integrity in vivo, maintains a certain level of stiffness, functions in bone support, proper joint mobility, and the like. In certain aspects, the permeability of the extracellular matrix of cartilage is particularly important. For example, the permeability of cartilage plays an important role in maintaining the structural integrity of the extracellular matrix of cartilage and maintaining the viability of chondrocytes. In certain embodiments, a decrease in the permeability of the extracellular matrix of cartilage can be associated with an increase in the viability of chondrocytes and a decrease in the structural integrity of the extracellular matrix of cartilage.

[0038] The biomaterial(s) described herein (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs) can be placed in a solution (e.g., vitrification solution, etc.) designed to prevent or reduce loss of biomaterial properties (e.g., cell viability, extracellular matrix integrity, or a combination thereof), and in some aspects, the solution can be animal product-free (e.g., FBS-free) or animal product-containing (e.g., FBS-containing). It should be noted that the following description and embodiments also apply to solutions containing animal products that contain biomaterials. In some aspects, the biomaterial(s) (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs) are at least partially immersed in the solution (e.g., while the biomaterial(s) are contained within a cassette of the present disclosure), and in other aspects, the biomaterial is fully immersed in the solution (e.g., while the biomaterial(s) are contained within a cassette of the present disclosure).

[0039] In one embodiment, the solution may be an extracellular type solution that includes at least one agent that prevents or reduces the loss of biomaterial properties (e.g., cell viability, extracellular matrix integrity, or a combination thereof). For example, the extracellular type solution may include an isotonic, plasma-like solution with an ionic complement that mimics the normal extracellular environment of the cells and tissues of the biomaterial(s) (e.g., natural tissues and / or bioengineered tissues such as bioengineered constructs). These isotonic, plasma-like solutions may include cell culture media that provide various amino acids and metabolites to the biomaterial (e.g., cells and / or tissues) for nutritional support. For example, cell culture media used in the extracellular type solution may include, but are not limited to, Dulbecco's Modified Eagle Medium (DMEM), αMEM, Glasgow MEM, Ham's F10, Ham's F-12, Leibovitz's L-15, Iscove's Modified DMEM, DMEM / Ham's F-12, and derivatives thereof. The extracellular type solution can be animal product free, such that the cell solution is free of animal products prior to placing the biomaterial (e.g., natural and / or bioengineered tissue, such as a bioengineered construct) into the cell solution. For example, if cell culture medium is used, the cell culture medium does not contain fetal bovine serum (FBS) or any other products of animal origin.

[0040] In certain embodiments, the solution (e.g., vitrification solution, etc.) comprises an intracellular type solution. The intracellular type solution can include, but is not limited to, an isotonic solution formulated to limit the passive exchange of water and ions between the cells in the biomaterial (e.g., natural tissue and / or bioengineered tissue, such as bioengineered constructs) and the intracellular type solution during storage. For example, the intracellular type solution can include a non-permeant anion, such as lactobionate or gluconate, to partially replace chloride ions in the extracellular space and provide osmotic support to balance the intracellular oncogenic pressure generated by cytoplasmic macromolecules and their associated counterions trapped within the cells. Intracellular type solutions include, but are not limited to, VIASPAN® (i.e., Belzer's Solution) and UNISOL® (e.g., SPS-1). Similar to the extracellular type solutions described above, the intracellular type solutions can be free of animal products.

[0041] Additional agents / ingredients can be added to the solution (e.g., vitrification solution, etc.) to further supplement the solution and further promote the viability of the biomaterial. For example, these additional agents / ingredients can provide additional nutritional support to the biomaterial(s) (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs), thereby reducing or preventing loss of viability of the biomaterial(s) (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs). These additional agents / ingredients can include, but are not limited to, nutrient cocktails having non-animal-derived (i.e., synthetically derived) essential amino acids, synthetically derived non-essential amino acids, synthetically derived vitamins, synthetically derived lipids, synthetically derived carbohydrates, or any combination thereof. Examples of carbohydrates included in the nutrient cocktail can further include saccharides and / or derivatives thereof (e.g., glucose, glycerol, sucrose, trehalose, fructose, galactose, maltose, lactose, etc.), or combinations thereof. Examples of amino acids provided in the cocktail can include, but are not limited to, glycine, L-arginine, L-cystine, L-glutamine, L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-serine, L-threonine, L-tryptophan, L-tyrosine, L-valine, or any combination of salts thereof. Examples of vitamins provided in the cocktail can include, but are not limited to, choline, D-calcium, folic acid, niacinamide, pyridoxine, riboflavin, thiamine, inositol, or any combination of salts thereof. In some embodiments, the agent can include one or more of Q-VD-OPH (quinoline-Val-Asp-difluorophenoxymethylketone), alpha-tocopherol, ferulic acid, curcumin, allene oxide synthase, and SDF-1.

[0042] In certain embodiments, the agent can reduce the loss of biomaterial properties (e.g., cell viability and / or extracellular matrix integrity) by, for example, 5% or more, 10% or more, 20% or more, 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 90% or more, or 99% or more, for example, compared to a control. In other words, the agent can substantially or completely inhibit the loss of biomaterial properties (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs), for example, by at least 80%, at least 85%, at least 90%, at least 95%, at least 99%, or 100%, for example, compared to a control.

[0043] In certain embodiments, the solution may comprise any of the following: 1 pM to 2 mM, 10 pM to 1 mM, 1 nM to 1 mM, 100 nM to 0.5 mM, 100 nM to 0.25 mM, 1 μM to 1 mM, 250 μM to 1 mM, 1 pM to 1000 μM, 1 pM to 500 μM, 1 pM to 30 μM, 1 pM to 1000 nM, 1 pM to 500 nM, 1 pM to 250 nM, 100 pM to 750 μM, 100 pM to 500 μM, 100 pM to 20 μM, 100 pM to 1000 nM, 1 pM to 750 nM, 1 pM to 500 nM, 1 pM to 250 nM, 1 pM~1nM, 500pM~500μM, 500pM~250μM, 500pM~100μM, 500pM~10μM, 500pM~1000nM, 500pM~750nM, 500pM~500nM, 500pM~250nM, 500pM~10 0nM, 500pM~1nM, 1nM~1000μM, 1nM~750μM, 1nM~500μM, 1nM~250μM, 1nM~100μM, 1pM~1μM, 100nM~1000μM, 100nM~750μM, 100nM~500μM, 1 00nM~250μM, 100nM~100μM, 100pM~1μM, 250nM~1000μM, 250nM~750μM, 250nM~500μM, 250nM~250μM, 250nM~100μM, 250nM~1μM, 500nM~1 000μM, 500nM~750μM, 500nM~500μM, 500nM~250μM, 100nM~100μM, 500nM~1μM, 750nM~1000μM, 750nM~750μM, 750nM~500μM, 750nM~250μM M, 750nM~100μM, 750nM~1μM, 0.5μM~1000μM, 10μM~950μM, 20μM~900μM, 30μM~850μM, 40μM~800μM, 50μM~750μM, 60μM~700μM, 70μM~650 μM, 80 μM ~ 600 μM, 90 μM ~ 550 μM, 100 μM ~ 500 μM, 110 μM ~ 450 μM, 120 μM ~ 400 μM, 130 μM ~ 350 μM, 140 μM ~ 300 μM, 150 μM ~ 250 μM, 160 μM ~ 200 μM, 0.and one or more of such agents at concentrations (in combination or for each agent individually) in the ranges of 5 μM to 100 μM, 1 μM to 90 μM, 5 μM to 90 μM, 10 μM to 85 μM, 10 μM to 75 μM, 20 μM to 85 μM, 20 μM to 65 μM, 30 μM to 70 μM, 30 μM to 50 μM, 40 μM to 80 μM, or 40 μM to 50 μM, where any concentration occurring within the above ranges can also serve as an endpoint of the range.

[0044] Vitrification can be achieved using a variety of cryoprotectant mixtures and cooling / warming conditions. Critical variables should be optimized for each specific extracellular tissue matrix type of biomaterial (e.g., natural and / or bioengineered tissues such as bioengineered constructs) and size of the individual biomaterial. The choice of cryoprotectant mixture, and the equilibration steps required for addition and removal of cryoprotectant without excessive osmotic shock, should be optimized based on the measured kinetics of cryoprotectant penetration in the biomaterial sample or by demonstration of viability and / or functionality. Freeze substitution can also be employed to confirm that ice-free preservation has been achieved with a given protocol.

[0045] Embodiments may include a stepwise cooling process, for example, where the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue such as bioengineered constructs) is cooled in a first solution containing a cryoprotectant to a first temperature between the temperature of the first solution (0 to +4°C) and -20°C, then further cooled to a second temperature in a second solution containing a cryoprotectant (at a higher concentration than the previous solution) at a temperature between the temperature of the first solution and -20°C, and the process may be repeated a third, fourth, fifth, sixth, seventh, etc. number of times until a desired cryoprotectant concentration and temperature is reached. In this regard, as discussed in more detail below, holes are present in both portions of the cassette of the present disclosure to allow the respective solutions to easily flow in and around each insert and biomaterial (and displace / replace the previous solution). In some embodiments, the flow of the respective solutions may be stopped for a predetermined time to allow the cassette to be immersed in the respective solutions during the CPA injection / removal steps and / or during the actual vitrification or storage.

[0046] The final cryoprotectant concentration of the vitrification solution can be determined by immersing the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) in a first solution containing a first cryoprotectant concentration (e.g., while the biomaterial(s) are contained within a cassette of the present disclosure), and then immersing the biomaterial(s) (e.g., while the biomaterial(s) are contained within a cassette of the present disclosure) in a second solution containing a second cryoprotectant concentration (which is higher than the first cryoprotectant concentration), and this process can be repeated a third, fourth, fifth, sixth, seventh, etc. number of times until the desired concentration is achieved.

[0047] The solution / vitrification preparation may include any combination of cryoprotectants. Suitable cryoprotectants include, in addition to those listed below, for example, dimethyl sulfoxide, 1,2-propanediol, ethylene glycol, n-dimethylformamide, and 1,3-propanediol, acetamide, agarose, alginic acid, alanine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, cyclohexanediol, dextran, diethylene glycol, dimethylacetamide, dimethylformamide, dimethylsulfoxide, erythritol, ethanol, ethylene glycol, ethylene glycol monomethyl ether, formamide, glucose, glycerol, glycerophosphate, glyceryl monoacetate, glycine, Hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, mannitol, mannose, methanol, methoxypropanediol, methylacetamide, methylformamide, methylurea, methylglucose, methylglycerol, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, proline, propylene glycol, propanediol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium nitrite, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine, xylose.

[0048] Other cryoprotectants that may be used are described in U.S. Pat. No. 6,395,467 to Fahy et al., U.S. Pat. No. 6,274,303 to Wowk et al., U.S. Pat. No. 6,194,137 to Khirabadi et al., U.S. Pat. No. 6,187,529 to Fahy et al., U.S. Pat. No. 5,962,214 to Fahy et al., U.S. Pat. No. 5,955,448 to Calaco et al., U.S. Pat. No. 5,629,145 to Meryman, and / or International Publication No. WO 02 / 32225, which corresponds to U.S. Pat. No. 6,740,484 to Khirabadi et al.

[0049] In some embodiments, prior to forming the at least one first bioengineered construct or natural tissue of the present disclosure, the method of the present disclosure may further comprise a step of immersing the at least one bioengineered construct or natural tissue in a pre-cryopreservation solution (e.g., comprising one or more of the aforementioned drugs and / or cryoprotectants) for a predetermined duration, such as a predetermined duration of at least 4 hours, or at least 6 hours, or at least 12 hours, or a predetermined duration ranging from 3 hours to 15 hours, or a predetermined duration ranging from 6 hours to 12 hours, or a predetermined duration ranging from 8 hours to 10 hours, a predetermined duration of about 9 hours, etc. In some embodiments, the pre-cryopreservation solution may comprise or may contain a drug selected from the group consisting of an antioxidant and a caspase inhibitor. Such drugs and / or the aforementioned drugs and / or cryoprotectants may be present in the pre-cryopreservation solution at a concentration of 1 pM to 2000 mM, 10 pM to 1000 mM, 1 nM to 100 mM, 100 nM to 0.25mM、1μM~1mM、250μM~1mM、1pM~1000μM、1pM~500μM、1pM~30μM、1pM~1000nM、1pM~500nM、1pM~250nM、100pM~750μM、100pM~500μM、100pM~20μM、100pM~1000nM、1pM~750nM、1pM~500nM、1pM~250nM、1pM~1nM、500pM~500μM、500pM~250μM、500pM~100μM、500pM~10μM、500pM~1000nM、500pM~750nM、500pM~500nM、500pM~250nM、500pM~100nM、500pM~1nM、1nM~1000μM、1nM~750μM、1nM~500μM、1nM~250μM、1nM~100μM、1pM~1μM、100nM~1000μM、100nM~750μM、100nM~500μM、100nM~250μM、100nM~100μM、100pM~1μM、250nM~1000μM、250nM~750μM、250nM~500μM、250nM~250μM、250nM~100μM、250nM~1μM、500nM~1000μM、500nM~750μM、500nM~500μM、500nM~250μM、100nM~100μM、500nM~1μM、750nM~1000μM、750nM~750μM、750nM~500μM、750nM~250μM、750nM~100μM、750nM~1μM、0.5μM~1000μM、10μM~950μM、20μM~900μM、30μM~850μM、40μM~800μM、50μM~750μM、60μM~700μM、70μM~650μM、80μM~600μM、90μM~550μM、100μM~500μM、110μM~450μM、120μM~400μM、130μM~350μM、140μM~300μM、150μM~250μM、160μM~200μM、0.These may be included in concentrations (in combination, or for each agent individually) ranging from 5 μM to 100 μM, 1 μM to 90 μM, 5 μM to 90 μM, 10 μM to 85 μM, 10 μM to 75 μM, 20 μM to 85 μM, 20 μM to 65 μM, 30 μM to 70 μM, 30 μM to 50 μM, 40 μM to 80 μM, or 40 μM to 50 μM, where any concentration occurring within the above ranges may also serve as an endpoint of the range.

[0050] The volumes of solutions employed in the methodologies of the present disclosure can vary considerably based on the size of the biomaterial (eg, natural tissue and / or bioengineered tissue, such as a bioengineered construct).

[0051] In embodiments, the solution comprises a cryoprotectant in an aqueous solution such as Euro-Collins solution, sterile water, salt solutions, culture media, and any physiological solution.

[0052] The final concentration of cryoprotectant in the solution used for preservation of the biomaterial(s) (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) may be any desired predetermined value, but will generally be about 70% cryoprotectant by weight or less (of the total weight of the preservation solution), e.g., about 65% cryoprotectant by weight or less, or about 60% cryoprotectant by weight or less. In some embodiments, the final concentration of cryoprotectant in the solution used for preservation may be in the range of about 50 to about 80% cryoprotectant by weight, or about 60 to about 75% cryoprotectant by weight, or about 68 to about 72% by weight (of the total weight of the preservation solution). However, in some embodiments (such as bioengineered cartilage), the final concentration of cryoprotectant in the solution used for preservation may be higher than the above concentrations.

[0053] In embodiments, the biological material to be preserved (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) may or may not have been previously exposed to a cryoprotectant.

[0054] In embodiments, the biomaterial(s) to be preserved (e.g., natural tissue and / or bioengineered tissue such as a bioengineered construct) may be immersed in (or exposed to) a solution in which the cryoprotectant concentration of the solution may be gradually increased, such as by using a linear or non-linear concentration gradient (e.g., for the solution flowing through the holes of the cassette of the present disclosure to contact the biomaterial(s)), to achieve a predetermined final solution cryoprotectant concentration, e.g., a cryoprotectant concentration of ≦70% by weight or less. In such embodiments, the concentration gradient is a linear or non-linear concentration gradient in which a cryoprotectant-free solution (e.g., the cryoprotectant-free solution initially present in the cassette of the present disclosure and contacting the biomaterial(s) configured in the cassette) is gradually replaced with a desired solution, such as a solution having a cryoprotectant concentration of ≦70% by weight.

[0055] For example, the cryoprotectant-free solution (e.g., initially present in the cassette of the present disclosure) may be substantially replaced with a predetermined solution, such as a solution having a cryoprotectant concentration of ≦70% by weight, in a time period of about 30 minutes, for example, in a time period of about 10 minutes, or in a time period of about 5 minutes. In embodiments, the rate at which the cryoprotectant-free solution is replaced with a predetermined solution, such as a solution having a cryoprotectant concentration of ≦70% by weight, should be slow enough to not kill most or all of the living cells present, and such rate will depend on the particular tissue / cells of the biomaterial(s) (e.g., natural tissues and / or bioengineered tissues, such as bioengineered constructs) and the size of the individual biomaterial(s). In certain embodiments, the concentration change during vitrification is slow enough to achieve approximate osmotic equilibration. In other embodiments, the concentration change during vitrification is more rapid such that approximate osmotic equilibration is not achieved until the final concentrations are reached.

[0056] In embodiments, the concentration of the solution is increased stepwise to achieve a predetermined cryoprotectant concentration solution, such as a solution having a cryoprotectant concentration of 70% by weight or less. For example, in embodiments, the concentration of cryoprotectant may be added stepwise to achieve a particular plateau (e.g., as measured in a cassette of the present disclosure), and this plateau may be maintained for a predetermined time, for example, a predetermined time ranging from 3 minutes to 10 minutes, or a predetermined time ranging from 4 minutes to 6 minutes, or a predetermined time of about 5 minutes. In certain embodiments, the concentration of cryoprotectant may be added stepwise to achieve a particular plateau, and this plateau may be maintained for a time sufficient to achieve approximate osmotic equilibration, such as 5 minutes or more, or about 10 minutes or more, or about 15 minutes or more. Additional cryoprotectant may then be added to the first cryoprotectant solution to increase the cryoprotectant concentration, or a second solution with a more concentrated cryoprotectant may be substituted for the first cryoprotectant solution. Then, after maintaining the concentration for a predetermined time (e.g., corresponding to those described above), or for a time sufficient to achieve approximate osmotic equilibration, additional cryoprotectant may be added, or a more concentrated one may be substituted, in one or more steps to achieve the desired concentration, e.g., a cryoprotectant concentration of ≦70% by weight.

[0057] In embodiments, there may be any number of cryoprotectant concentration plateaus and / or steps, such as any integer between 2 and 10, before a desired concentration, such as a cryoprotectant concentration of ≦70% by weight, is reached. For example, in embodiments, four cryoprotectant concentration plateaus may be used before a desired concentration, such as a cryoprotectant concentration of ≦70% by weight, is reached.

[0058] In some embodiments, there may be six steps, with the first step using a cryoprotectant-free solution, followed by four plateaus of increasing cryoprotectant concentration, followed by a final pre-determined cryoprotectant concentration, e.g., a cryoprotectant concentration of ≦70% by weight. For example, in such an embodiment where the final pre-determined cryoprotectant concentration is about 70% by weight cryoprotectant, step 1 may use no cryoprotectant, step 2 may use about 5 to about 20% of the final cryoprotectant concentration, e.g., about 10 to about 15%, step 3 may use about 15 to about 35% of the final cryoprotectant concentration, e.g., about 20 to about 30%, step 4 may use about 40 to about 60% of the final cryoprotectant concentration, e.g., about 45 to about 55%, step 5 may use about 65 to about 85% of the final cryoprotectant concentration, e.g., about 70 to about 80%, and step 6 may use a final cryoprotectant concentration that is about 70% by weight cryoprotectant. In some embodiments, each cryoprotectant concentration step may be for a predetermined duration, e.g., a predetermined duration in the range of 3 minutes to 10 minutes, or a predetermined duration in the range of 4 minutes to 6 minutes, or a predetermined duration of about 5 minutes. In some embodiments, each cryoprotectant concentration step may be maintained for a time sufficient to achieve approximate osmotic equilibration.

[0059] For example, in some embodiments, the at least one bioengineered construct or natural tissue sample is immersed in 1-6 different solutions, or a series of solutions with decreasing concentrations of the cryoprotectant is obtained via a linear or non-linear concentration gradient. In some embodiments, the at least one bioengineered construct or natural tissue sample is immersed in the 1-6 different solutions, and the at least one bioengineered construct or natural tissue sample is immersed in each of the different solutions for 5 minutes or less.

[0060] In some embodiments, the disclosed method includes the steps of: (i) immersing the at least one bioengineered construct or natural tissue sample in a series of solutions with increasing concentrations of cryoprotectant to form at least one first bioengineered construct or natural tissue immersed in a final solution having a cryoprotectant concentration of 70% or less by weight; (ii) cooling the at least one first bioengineered construct or natural tissue in the final solution having a cryoprotectant concentration of 70% or less by weight to a temperature below the glass transition temperature of the final solution having a cryoprotectant concentration of 70% or less by weight; and (iii) immersing the at least one first bioengineered construct or natural tissue in a series of solutions with decreasing concentrations of the cryoprotectant to form at least one first bioengineered construct or natural tissue immersed in a final solution having a cryoprotectant concentration of 70% or less by weight. and obtaining at least one second bioengineered construct or natural tissue immersed in a solution substantially free of cryoprotectant, said at least one second bioengineered construct or natural tissue being a composition substantially free of cryoprotectant, wherein in step (iii) said at least one first bioengineered construct or natural tissue sample is immersed in 1 to 7 different solutions (and said at least one first bioengineered construct or natural tissue sample is immersed in each of said different solutions for no more than 5 minutes), or said series of solutions with increasing concentrations of cryoprotectant are obtained via a linear or non-linear concentration gradient.

[0061] After a biomaterial (e.g., a natural tissue and / or a bioengineered tissue, such as a bioengineered construct) is immersed in a solution containing a cryoprotectant at a concentration sufficient to reach a desired concentration, e.g., a cryoprotectant concentration of ≦70% by weight, the biomaterial(s) maintained in the solution containing the predetermined concentration of cryoprotectant can be rapidly cooled (preferably at a rate ranging from about 35° C. / min to about 55° C. / min, or at a rate of about 45° C. / min) to a temperature between about −20° C. and the glass transition temperature (e.g., while the biomaterial(s) are contained in a cassette of the present disclosure), e.g., to a temperature of about −100° C. In some embodiments, the rapid cooling rate can be about −15 to about −75° C. per minute. For example, the average cooling rate can be about −15 to about −75° C. per minute, e.g., about −30 to −60° C. per minute, or about −35 to −50° C. per minute, or about −43 to −47° C. per minute. The temperature to which the biomaterial(s) is cooled during this rapid cooling process is between about -20°C and the glass transition temperature of the final cryoprotectant solution at a cryoprotectant concentration of 70% by weight or less, for example, between about -80°C to about -180°C, or about -90°C to about -120°C, or to a temperature of about -100°C.

[0062] The biomaterial(s) (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) may also optionally be subjected to a slow cooling step after the rapid cooling step (e.g., while the biomaterial(s) are configured in a cassette of the present disclosure), in which the biomaterial(s) may be cooled to a predetermined storage temperature above the glass transition temperature at an average rate of less than 30° C. per minute, e.g., less than 10° C. per minute. The cooling step may be performed at an average rate of less than 5° C. per minute, or less than about 3° C. per minute. In embodiments, the cooling rate during the entire slow cooling step does not increase by more than 30° C. per minute, e.g., a cooling rate that does not increase by more than 10° C. per minute, or a cooling rate that does not increase by more than 5° C. per minute. In embodiments, the cooling rate (for single or multi-stage cooling processes) includes, for example, a cooling rate in the range of about 0.5 to about 10° C. / min, e.g., about 2 to about 8° C. / min, or about 4 to about 6° C. / min. In embodiments, the process is independent of the cooling rate, as long as ice formation is avoided. The temperature to which the biomaterial(s) are cooled during this slow cooling process is between about -110°C and about -180°C, or between about -125°C and about -145°C, or about -135°C.

[0063] In an embodiment, the slow cooling rate is achieved by altering the environment in which the vessel containing the solution is placed.

[0064] In some embodiments, a rapid cooling rate is achieved with the aid of additional liquid, such as optionally pre-chilled 2-methylbutane. The container (e.g., a cassette of the present disclosure) is then removed from the liquid and further cooled in a gaseous environment to the final storage temperature to achieve a slower cooling rate.

[0065] The biomaterial(s) (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) can be stored for a period of time at a temperature below -20°C and below the glass transition temperature (e.g., while the biomaterial(s) are configured within a cassette of the present disclosure). For example, after the cooling step described above, the biomaterial(s) can be stored at a temperature between about -110°C to about -180°C, or about -125°C to about -145°C, or about -135°C.

[0066] In some embodiments, the method may further include a transport step in which the biomaterial (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) is transported (e.g., while the biomaterial(s) are contained in the cassette of the present disclosure). In embodiments, the biomaterial(s) are transported at a temperature between the glass transition temperature of the final full strength solution and -20°C, e.g., about 20°C to 80°C higher than the glass transition temperature of the full strength cryoprotectant solution, e.g., 40°C to 60°C higher than the glass transition temperature of a given full strength cryoprotectant solution, e.g., a solution having a cryoprotectant concentration of ≦70% by weight, or a solution having a cryoprotectant concentration of ≦70% by weight. For example, the biomaterial(s) may be transported on dry ice at about -79.6°C.

[0067] After storage, the biomaterial(s) (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues) can be removed from the predetermined maximum strength cryoprotectant solution. The method for removing the biomaterial(s) from the predetermined maximum strength cryoprotectant solution can include slowly warming the biomaterial(s) in the predetermined maximum strength cryoprotectant solution to a warming temperature ranging between -20°C and the glass transition temperature of the cryoprotectant solution (e.g., while the biomaterial(s) are configured in a cassette of the present disclosure). A slow warming rate of less than 50°C per minute can be used to warm the biomaterial(s) in the predetermined maximum strength cryoprotectant solution. In embodiments, the average warming rate during this stage can be about 10-40°C per minute, e.g., about 25-35°C per minute. Additionally, the temperature to which the stored biomaterial(s) is slowly warmed can be about -30°C to -80°C, e.g., about -45°C to -65°C.

[0068] After the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) has undergone this optional slow warming process, the biomaterial(s) may then be rapidly warmed to a temperature greater than -20°C (e.g., while the biomaterial(s) are configured within a cassette of the present disclosure). In embodiments, the temperature should be high enough so that the solution is sufficiently fluid so that the biomaterial(s) may be removed therefrom. The rapid warming process may be carried out at a rate greater than about 80°C per minute, e.g., greater than about 100°C per minute. The average warming rate during this step may be about 200-300°C per minute, e.g., about 215-250°C per minute. In embodiments, the biomaterial(s) may be warmed to a temperature greater than about -20°C, e.g., greater than about -10°C, or greater than about -5°C, e.g., between about -5°C and about 5°C. In embodiments, the process is independent of the warming rate, so long as ice formation is avoided.

[0069] In embodiments, a rapid warming rate can be achieved by changing the environment in which the container containing the solution is placed. In embodiments, a slower warming rate can be achieved by placing the container (e.g., a cassette of the present disclosure) in a gaseous environment at a temperature above the temperature at which the biomaterial(s) (e.g., natural tissue such as a bioengineered construct and / or bioengineered tissue) are stored. The container can then be placed in the coil of an induction heating system or in a liquid, such as, for example, an aqueous solution of dimethyl sulfoxide (DMSO), at a temperature above -75°C, e.g., above 0°C, or at normal atmospheric temperature, to achieve a rapid warming rate.

[0070] In embodiments, after the biomaterial(s) (e.g., natural and / or bioengineered tissues such as bioengineered constructs) are warmed to a temperature above -65°C, the concentration of the cryoprotectant in the solution can be decreased in a gradient or stepwise manner, e.g., by reversing the steps described above to increase the concentration of the cryoprotectant (e.g., while the biomaterial(s) are in a cassette of the present disclosure). For example, in embodiments, the biomaterial(s) in which the cryoprotectant concentration is to be decreased can be immersed (or exposed) to a solution in which the cryoprotectant concentration of the solution can be gradually decreased, such as by using a linear or non-linear concentration gradient, to achieve a nearly cryoprotectant-free or cryoprotectant-free solution. In embodiments, the concentration gradient is a linear or non-linear concentration gradient in which a solution having a cryoprotectant concentration of a predetermined maximum strength cryoprotectant solution, e.g., a solution having a cryoprotectant concentration of ≦70% by weight, is gradually replaced with a cryoprotectant-free solution.

[0071] In embodiments, the cryoprotectant concentration is decreased in a stepwise manner (e.g., while the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) are contained in a cassette of the present disclosure). In embodiments, decreasing the cryoprotectant concentration of the tissue may be accomplished by immersing the tissue in a series of solutions of decreasing cryoprotectant concentrations to facilitate elution of the cryoprotectant from the tissue. The solutions are generally at about -15°C or above, e.g., from about -15°C to about 15°C, or from about 0°C to about 10°C.

[0072] In embodiments, the cryoprotectant concentration may be reduced to achieve a particular plateau, which may be maintained for a period of time, for example, a period ranging from 3 minutes to 10 minutes, or a period ranging from 4 minutes to 6 minutes, or a period of about 5 minutes. In some embodiments, the cryoprotectant concentration may be reduced to achieve a particular plateau, which may be maintained for a time sufficient to achieve approximate osmotic equilibration.

[0073] The cryoprotectant concentration may then be further reduced, which may or may not provide a cryoprotectant-free solution. If not, optionally, the concentration may be maintained for a sufficient time to achieve approximate osmotic equilibrium, after which the cryoprotectant concentration may again be further reduced in one or more steps to finally provide a cryoprotectant-free solution. In embodiments, the tissue may be immersed in each solution for a predetermined period of time, for example, a predetermined period of time ranging from 3 minutes to 10 minutes, or a predetermined period of time ranging from 4 minutes to 6 minutes, or a predetermined period of time of about 5 minutes.

[0074] To reduce the cryoprotectant concentration, the cryoprotectant solution may be mixed with a solution of the same type as the cryoprotectant-free solution utilized in adding the cryoprotectant to the biomaterial(s) (e.g., natural and / or bioengineered tissues, such as bioengineered constructs). The solution may also include at least one osmotic buffer.

[0075] As used herein, "osmotic buffering agent" refers to a non-permeating extracellular solute of low or high molecular weight that counteracts the osmotic effect of a cryoprotectant at a higher intracellular concentration than the extracellular concentration during the cryoprotectant extrusion process.

[0076] As used herein, "non-penetrating" means that the majority of the molecules of a chemical do not penetrate into the cells of the biomaterial(s) (e.g., natural and / or bioengineered tissues, such as bioengineered constructs), but instead remain in the extracellular fluid of the biomaterial.

[0077] As used herein, "low molecular weight" refers to, for example, a relative molecular weight of 1,000 Daltons or less. As used herein, "low molecular weight osmotic buffering agents" have a relative molecular weight of 1,000 Daltons or less. Low molecular weight osmotic buffering agents include, for example, maltose, potassium and sodium fructose 1,6 diphosphate, potassium and sodium lactobionate, potassium and sodium glycerophosphate, maltopentose, stachyose, mannitol, sucrose, trehalose, glucose, maltotriose, sodium and potassium gluconate, sodium and potassium glucose 6 phosphate, and raffinose. In an embodiment, the low molecular weight osmotic buffering agent is at least one of mannitol, sucrose, trehalose, and raffinose.

[0078] As used herein, "high molecular weight" refers to, for example, a relative molecular weight of more than 1,000 daltons to less than 500,000 daltons. As used herein, "high molecular weight cryoprotectants and osmotic buffering agents" generally have a relative molecular weight of more than 1,000 daltons to less than 500,000 daltons. Examples of high molecular weight osmotic buffering agents include hydroxyethyl starch (HES), polyvinylpyrrolidone (PVP), raffinose undecaacetate (more than 1,000 daltons) and ficoll (more than 1,000 to 100,000 daltons). In an embodiment, the high molecular weight osmotic buffering agent is HES, such as HES having a molecular weight of about 450,000.

[0079] The cryoprotectant-free solution may contain less than about 500 mM of an osmotic buffer, for example, about 200 to 400 mM of an osmotic buffer. As the osmotic buffer, a low molecular weight osmotic buffer may be used. In an embodiment, the low molecular weight osmotic buffer is mannitol.

[0080] In embodiments, the cryoprotectant can be removed in a series of steps, such as 3 steps, 4 steps, 5 steps, 6 steps, 7 steps, etc. In embodiments, the cryoprotectant may be removed in a series of 7 steps, where in step 1, the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue, such as a bioengineered construct) may be exposed to a cryoprotectant solution at a concentration that may be about 40 to about 70%, e.g., about 45 to about 55%, of the highest cryoprotectant concentration used, and in step 2, the biomaterial(s) may be exposed to a cryoprotectant concentration that may be about 30 to about 45%, e.g., about 35 to about 40%, of the highest cryoprotectant concentration used. In step 3, the biomaterial(s) may be exposed to a cryoprotectant concentration that is about 15 to about 35%, for example about 20 to about 30%, of the highest cryoprotectant concentration used; in step 4, the biomaterial(s) may be exposed to a cryoprotectant concentration that is about 5 to about 20%, for example about 10 to about 15%, of the cryoprotectant concentration used; and in step 5, the biomaterial(s) may be exposed to a concentration that is about 2.5 to about 10%, for example about 5 to about 7.5%, of the cryoprotectant concentration used. In the above steps, the remainder of the solution may include an osmotic buffer and may be a solution that does not contain a cryoprotectant. In step 6, substantially all of the cryoprotectant may be removed and the osmotic buffer may be retained. In step 7, the osmotic buffer may be removed. In embodiments, steps 6 and 7 may be combined in a single step. For example, the osmotic buffer may be removed simultaneously with the remaining cryoprotectant. In embodiments, if an osmotic buffer is not used or is not removed, step 7 may be omitted. Each of these concentration steps may be maintained for a time sufficient to achieve approximate osmotic equilibration, such as about 10-30 minutes, or 15-25 minutes. In some embodiments, each of the concentration steps may be maintained for about 4-6 minutes, or about 5 minutes. In embodiments, the cryoprotectant is removed with one or more washes using a cryoprotectant-free solution.

[0081] The temperature of the series of solutions used to remove the cryoprotectant from the biomaterial(s) (e.g., natural and / or bioengineered tissues, such as bioengineered constructs) may be about -15°C or higher, e.g., from about -15 to about 15°C, or from about 0°C to about 37°C. In embodiments, step 1 may be initiated when the biomaterial(s) is at a temperature greater than about -75°C, e.g., greater than -65°C. In embodiments, the temperature of the biomaterial(s) may be less than the temperature of the solution in which it is immersed in step 1, and the biomaterial(s) may be further warmed to a temperature greater than about -15°C during step 1 of cryoprotectant removal.

[0082] The cryoprotectant-free solution employed for washing the biomaterial(s) (e.g., natural tissue and / or bioengineered tissue such as bioengineered constructs) can be sterile water, a physiological salt solution (e.g., saline, Hank's Balanced Salt Solution, Lactated Ringers Solution or Krebs-Henseliet Solution), or a tissue culture medium employed for tissues such as mammalian cells (e.g., Roswell Park Memorial Institute Medium, Dulbecco's Modified Eagle's Medium (DMEM), Eagle's Medium or Medium 199).

[0083] The number of washes, the volume of each wash, and the time of each wash may vary depending on the particular biomaterial mass and the desired final residual chemical concentration. In embodiments, the final wash (rinse) may be performed in a commonly used medical salt solution, such as saline or Ringer's solution.

[0084] In some embodiments, the methodology of the present disclosure can be carried out in a vial or deep well plate. Alternatively, the methodology of the present disclosure can be carried out in a specially designed cassette of the present disclosure that is made suitable for use in vitrification processes. The cassette of the present disclosure can be used as part of a high-throughput system that can store multiple biomaterials at once (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues).

[0085] The biggest hurdle in storing multiple constructs at once is the ability to generate and maintain adequate cooling and rewarming rates such that ice formation is prevented. Previous work related to the cryopreservation of cells on plates has revealed that the configuration of the system has a significant impact on its ability to cool and warm without ice formation. Initially, it was thought that vitrification of constructs could be accomplished using multi-well culture plates (similar to those in which constructs are typically shipped to end users).

[0086] However, the design of such plates makes them difficult to use for low temperature (i.e. cryogenic) storage. Traditional multi-well culture plate designs make it difficult to place them in cooling and heating baths without the contents of the bath flowing into the wells. Deep well plates are designed to accommodate larger volumes and reduce the risk of wicking into the wells.

[0087] The methodology described above in this disclosure was used to successfully vitrify six constructs at a time using deep well plates, however vitrification of more than six constructs at a time showed reduced viability due to prolonged exposure to CPAs causing cytotoxicity.

[0088] In embodiments, deep well plates for use with the methodology of the present disclosure should be made from a different plastic (i.e., polypropylene versus polystyrene) compared to conventional tissue culture plates. Polypropylene has been shown to be more susceptible to vitrification and low temperatures by providing better conductivity for cooling and warming biomaterials (e.g., natural and / or bioengineered tissues, such as bioengineered constructs). More consistent and faster cooling and warming rates have been achieved.

[0089] In some embodiments, the above methodologies of the present disclosure may be implemented in specially designed cassettes of the present disclosure adapted for use in vitrification processes. The cassettes of the present disclosure may be used as part of a high-throughput system capable of storing multiple biomaterials (e.g., natural tissues such as bioengineered constructs and / or bioengineered tissues) at once.

[0090] For example, the methodology of the present disclosure may be performed in a cassette designed to hold 24 biomaterial samples (e.g., natural and / or bioengineered tissues such as bioengineered constructs) in place within well inserts while providing sufficient space and access for the biomaterials to be exposed to the vitrification solution. The cassette is configured to be moved as a unit, reducing the time between steps and making the injection / removal steps more seamless. Additionally, the configuration of the inserts within the cassette can be set to mimic the configuration of the wells within a 24-well plate, such that the deposition of the inserts into the cassette and their return to the plate after rewarming can also be seamless and does not require handling of individual biomaterials (this is particularly advantageous compared to protocols that require each biomaterial to be moved individually, limiting the number of individual biomaterials that can be vitrified at one time). Fragments of the cassette can be easily modified for other types of native / natural tissues and / or bioengineered constructs and are highly suitable for use in an automated setting where multiple biomaterial samples (herein the terms biomaterial(s) and biomaterial sample(s) are used interchangeably) can be processed, vitrified and rewarmed as one unit.

[0091] Such a cassette can have two parts (e.g., a top and a bottom) that fit together to hold a predetermined amount of well inserts (the exemplary embodiment depicted and described below has 24 well inserts, but the predetermined amount of well inserts can range from 6 to 384, such as 12 to 192, or 24 to 96, or 24 to 48). The top has a placeholder to hold the inserts in place in a configuration that fits a predetermined well array, such as the well array of a 24-well plate. This configuration makes it easy to move each biomaterial sample from the cassette to a multi-well plate as needed. Holes may be present in both parts of the cassette to allow the vitrification solution to easily flow in and around each insert and biomaterial, so that the cassette can be immersed in vitrification solution during the CPA injection / removal steps and the actual vitrification. In embodiments, the placeholder can be easily modified to hold fragments of native tissue for preservation as well.

[0092] In embodiments, the cassettes may be configured such that the entire vitrification process may be automated. The cassettes of the present disclosure, which may hold multiple biomaterial samples (e.g., natural and / or bioengineered tissues such as bioengineered constructs) at one time, allow for the processing of multiple samples from a commercial source in a reproducible manner (e.g., up to 384 biomaterials at one time, or 24 biomaterials at one time as depicted below). The use of the cassettes of the present disclosure allows for the improvement of vitrification methods by reducing handling errors and improving product quality while being able to practically process batches of constructs and / or tissues with a higher level of precision while ensuring a high level of viability for each specimen for banking.

[0093] Such an exemplary cassette of the present disclosure is illustrated in FIG. 1 below. FIG. 1 illustrates an exemplary cassette (100) having a first portion (102) and a second portion (104) configured to mate with one another via a releasable locking means, with one or more spaces in a sidewall (118) of the second portion configured to receive one or more protruding structures (106) of the second portion (104). Holes (108, 116) are present in both the first portion (102) and the second portion (104) of the cassette (100) to allow fluids (e.g., vitrification solutions or solutions used during the vitrification process) to easily flow through the cassette (100). The second portion (104), which may be the top of the cassette (100), has a placeholder (110) for holding an insert (see (120) in FIG. 2) in place in a configuration that matches the well arrangement of a well plate (not shown). This configuration facilitates the transfer of biological samples from the cassette to the plate as needed.

[0094] Figure 2A shows an exemplary cassette as one piece and how the biomaterial (122) in the insert (124) fits into the cassette. Figure 2B shows a side view of the cassette closed. Figure 2C shows a side view of the cassette with the lid removed. Figure 2D illustrates two sides of the cassette with a biomaterial sample placed on one side, and Figure 2E illustrates a side view of both sides of the cassette.

[0095] As shown in Figures 2A and 2D, holes (108, 116) are present in both the first portion (102) and the second portion (104) of the cassette (100) to allow fluid (e.g., vitrification solution or solutions used during the vitrification process) to easily flow through the cassette and around each insert (124) and biomaterial (122).

[0096] 3 is a photograph of an exemplary cassette showing the relative relationships of the parts of the exemplary cassette. The cassette has two parts, both with holes to allow solutions to easily reach the biomaterial. The lid contains a round placeholder to hold the well insert containing the biomaterial in place within the cassette.

[0097] In some embodiments, the cassettes of the present disclosure can be made from plastics such as those traditionally used in the manufacture of laboratory equipment for research and medical purposes, particularly plastic formulations that can withstand exposure to the cryogenic temperatures and chemicals used in the vitrification process, hi some embodiments, the plastic can be polypropylene or Teflon.

[0098] The cassettes of the present disclosure may be reusable or disposable.

[0099] The cassettes of the present disclosure may be manufactured using conventional methods such as, for example, injection molding.

[0100] The cassettes of the present disclosure may alternatively be manufactured using reaction injection molding techniques in which a prepolymer is injected into a mold instead of using a molten polymeric material. After injection, the prepolymer polymerizes and hardens to form the finished portion of the cassette of the present disclosure. In addition, prepolymers are generally less viscous than molten polymers and therefore may flow more easily into a mold, reducing mold construction costs.

[0101] In some embodiments, a cassette of the present disclosure may be a reusable or disposable multi-sample cassette including a first portion and a second portion configured to fit together via a releasable locking mechanism, the second portion including one or more inserts and a plurality of placeholders, each placeholder of the plurality of placeholders configured to receive one of the one or more inserts, each of the one or more inserts including at least one bioengineered construct or natural tissue sample, the first portion and the second portion including a plurality of openings configured to allow solution to flow through and around each of the one or more inserts and the at least one bioengineered construct or natural tissue sample, and the configuration of the placeholders in the cassette is configured to mimic the configuration of wells in a plate having a predetermined number of wells, the predetermined number of wells being in the range of 6-384.

[0102] In embodiments, the releasable locking mechanisms may be those depicted above and / or mechanisms that rely on an initial spatial deflection of at least one element of the locking component to engage the releasable locking component. These may be, for example, bayonet tabs with detents that engage against a coupling element of the other locking component, followed by a spatial re-deflection of at least one element to hook onto one or more elements of the other locking component. The detents and coupling components are adapted to be releasable by making the detents relatively small so that low force is required to disengage them from the coupling configuration. The coupling components may be bars or edges of an opening through which the bayonet tabs can protrude.

[0103] Alternative methods of releasably connecting the first and second parts include, for example, the use of a ball and socket, where the ball part fits into a socket that is slightly smaller than the diameter of the ball. Similar to a tab and detent system, manual application of force to force the ball into the socket deforms one or both parts, allowing them to pass past each other to the first locked position. Locking elements can be located along the outer edges of the first and second parts. For large reusable or disposable multi-sample cassettes (e.g., containing 384 wells), multiple large locks can be located along each side to help keep the first and second parts securely secured. In some embodiments, when the releasable lock is moved to the final locked position with the second and third locking elements engaged, a space is created between the engaged locking elements and the lid or tray. This space can be varied in size by appropriate sizing of the locking elements and / or to provide a handle for manual manipulation of the reusable or disposable multi-sample cassette.

[0104] In an embodiment, the first portion may have a frame having a predetermined thickness, such as about 0.5 to about 3 mm, or about 1 to about 2 mm, or about 1.3 to about 1.8 mm, or about 1.4 to about 1.6 mm, etc. In an embodiment, the second portion may have a frame having a predetermined thickness, such as about 0.5 to about 3 mm, or about 1 to about 2 mm, or about 1.3 to about 1.8 mm, or about 1.4 to about 1.6 mm, etc.

[0105] In embodiments, each opening of the plurality of openings (which may be in the form of any desired shape, such as a circle or a hexagon) may have a diameter in the range of about 3 to about 7 mm, or about 4 to about 6 mm, or about 4.5 to about 5.5 mm, or about 4.8 to about 5.2 mm. In addition, each opening of the plurality of openings may be spaced a predetermined distance from the nearest adjacent opening, for example, a distance in the range of about 3 to about 15 mm, or about 5 to about 12 mm, or about 7 to about 10 mm, or about 8 to about 9 mm. In some embodiments, the diameter of each opening of the plurality of openings is the same on both the first portion and the second portion. In other embodiments, the diameter of each opening of the plurality of openings on the first portion is different from the diameter of each opening of the plurality of openings on the first portion.

[0106] In some embodiments, the area of ​​the interior of the cassette (when the first and second portions are engaged) is about 89 cm 2 ~Approx. 101cm 2 , or about 92 cm 2 ~Approx. 98cm 2 , or about 94 cm 2 ~Approx. 96cm 2 , or about 94.5 cm 2 ~Approx. 95.5cm 2 Alternatively, the area may be set to a predetermined area, such as an area in the range of 100 mm to 150 mm.

[0107] In some embodiments, the total volume of the interior chamber of the reusable or disposable multi-sample cassette (when the first and second portions are engaged) is about 81 cm 3 ~Approx. 98cm 3 , or about 86 cm 3 ~about 95cm 3 , or about 89 cm 3 ~Approx. 92cm 3 may be in the range.

[0108] In some embodiments, the volume of each bioengineered construct or native tissue sample contained in the cassette is about 1 cm 3 ~approx. 1.5cm 3 , or about 1.1 cm 3 ~approx. 1.4cm3 , or about 1.1 cm 3 ~approx. 1.3cm 3 Such a single bioengineered construct or natural tissue sample can be immobilized / immobilized on the surface of one or more inserts by conventional methods known to those skilled in the art.

[0109] In some embodiments, the first and / or second parts may be disposable or reusable. In this regard, the first and / or second parts, or parts thereof, may be made of, but are not limited to, polyolefins such as polyethylene and / or copolymers thereof, including low density, high density, linear low density, or very low density polyethylene, polypropylene and / or polypropylene copolymers, including atactic polypropylene, isotactic polypropylene, syndiotactic polypropylene, and / or combinations thereof, or may be made of plastic materials such as polybutylene. In other embodiments, the disposable or reusable first and / or second parts may be made of glass, or ceramic materials, or the like.

[0110] In some embodiments, the first and second portions may be formed from a medical grade plastic material, such as medical grade polypropylene, polystyrene, or Teflon. The first and second portions may be formed from a transparent or translucent plastic material or may include transparent or translucent portions (made from medical grade polypropylene, polystyrene, Teflon, or other plastics) that allow a user or operator to observe one or more biomaterials contained therein. In such embodiments, only selected portions of the first and / or second portions may be transparent or translucent, with other portions of the first and second portions being formed from an opaque reflective material.

[0111] In embodiments, the present disclosure provides an apparatus (such as a perfusion apparatus) for supplying the above-mentioned solutions to the cassette of the present disclosure. The perfusion apparatus is in fluid communication with the internal chambers of the cassette of the present disclosure that contain biomaterials (e.g., natural tissues and / or bioengineered tissues such as bioengineered constructs) and includes at least one solution source well that controllably provides a source of each solution for fresh medium to one chamber containing the biomaterial(s) and a waste well in fluid communication with the chambers of the cassette and that controllably receives spent medium and / or fluids flowing out of the cassette.

[0112] Specific and preferred values ​​disclosed for components, ingredients, additives, dimensions, conditions, and similar aspects, as well as ranges thereof, are for illustrative purposes only and do not exclude other defined values ​​or other values ​​within defined ranges. The disclosed apparatus and methods can include any or any combination of the values, specific values, more specific values, and preferred values ​​set forth herein, including any express or implied intermediate values ​​and ranges. EXAMPLES

[0113] [method] <Tissue culture> The human epidermis model was obtained commercially and maintained according to its specifications. All constructs were incubated in appropriate media under physiological tissue culture conditions for 24 h before starting the experiments. Fresh controls were used in each experiment and experimental treatment groups were evaluated over a period of 4–5 days after rewarming.

[0114] <Vitrification method> To achieve the final cryoprotectant concentration, the constructs were gradually infiltrated with vitrification solution pre-cooled at 4°C in six stages of 0%, 12.5%, 25%, 50%, 75% and 100% of each formulation. After rewarming, the vitrification solution was sequentially removed into culture medium in seven stages at 4°C as previously described. (See Non-Patent Document 15: Vitreous cryopreservation maintaining the function of vascular grafts, Nature Biotechnology, 8(3):296-9, Epub 2000 / 03 / 04, doi:10.1038 / 73737, PubMed PMID: 10700144 (2000); Song et al., Vitreous Preservation of Rabbit Articular Cartilage, Cell Preservation Technology, 2 (1); 67-74 (2004)).

[0115] Constructs, once filled with vitrification solution, can be cooled and rewarmed to storage temperature using several methods. (1) Constructs were placed in glass scintillation vials (diameter x height, 25 mm x 60 mm) with 1.5 mL of pre-cooled vitrification solution and 0.3 mL of solution in the well insert. Next, 1 mL of 2-methylbutane (isopentane, freezing point: -160 °C, density: 0.62) was placed on top of the vitrification solution in the vial and 0.2 mL in the well insert at 4 °C, ensuring no direct air contact. Samples were placed in a pre-cooling bath containing isopentane in a mechanical storage freezer at -135 °C and rapidly cooled (approximately 45 °C / min) to -100 °C. Once -100 °C was reached, samples were removed from the bath and stored at -135 °C in a mechanical storage freezer with slow cooling (3 °C / min) to -135 °C. Samples were kept at -135 °C for a minimum of 24 hours. Rewarming of constructs was performed in two stages. First, they were slowly warmed (~30 °C / min) to -100 °C in the top of a mechanical storage freezer, then rapidly warmed (~225 °C / min) to 0 °C or ±-10 °C in a room temperature 30% ME2SO bath. (2) The constructs were inserted into the wells of a deep-well plate. 0.6 mL of vitrification solution was placed in the wells and 0.2 mL of solution in the inserts. To cool the plates, they were placed in a shallow pre-cooling bath containing isopentane in a -135 °C mechanical storage freezer for ~5 min, after which the plates were removed from the bath and left in the -135 °C mechanical storage freezer for slow cooling to -135 °C for storage. For rewarming, the plates were removed from the freezer and left at room temperature to slowly rewarm the samples to ~-100 °C, after which rapid rewarming was performed by placing the deep-well plates in a room temperature 30% ME2SO bath until the samples no longer vitrified. (3) The last method is to load the construct into an insert and place it in a specially made cassette. Once the loading step is complete, the cassette is placed into a pouch containing approximately 150 mL of vitrification solution, evacuated and sealed with a bag sealer. The bag is then placed in a pre-cooling bath containing isopentane overnight in a mechanical storage freezer at -135 °C. The next day, the bag is removed from the bath and stored at -135 °C.To rewarm, place the bag containing the cassette at -80 °C for 15 to 25 min to allow for slow cooling, then immerse the bag in a water bath at approximately 40 °C to rapidly warm it until the sample no longer vitrifies.

[0116] <Viability assay> (Resazurin Assay) It is used to measure metabolic activity and has the advantage that it is non-toxic and therefore allows the evaluation of the constructs several times before and after treatment. Resazurin dye (alamarBlue) was used to evaluate cell viability by measuring the oxidation / reduction reactions occurring within the cells. The dye was added directly to the culture wells and the plates were incubated at 37°C for 3 hours. Upon reduction, the dye changed color and was measured and quantified using a fluorescence microplate reader at an excitation wavelength of 544 nm and an emission wavelength of 590 nm.

[0117] (MTT assay) It was also used to measure metabolic activity. We included this assay because it is the most common assay used to assess skin equivalent viability. The MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay is based on the ability of mitochondrial dehydrogenase enzymes from viable cells to cleave the pale yellow tetrazolium ring of MTT and form dark blue formazan crystals that accumulate in healthy cells. Solubilization of the cells with detergent liberates the solubilized crystals. The number of viable cells is directly proportional to the level of formazan product produced and can be quantified using a simple colorimetric assay read in an absorbance reader.

[0118] (Dose-Response Assay) (Functional Endpoint Assay Required by MatTek for Quality Assurance) The dose-response assay was performed according to the manufacturer's instructions. Fresh tissues were used for the Triton Dose Response assay the next day, and the vitrified group was vitrified the next day. The test begins with the application of 100 μl of 1% Triton X-100 at time intervals of 4, 6, 8, and 12.5 hours. After Triton exposure, the tissue constructs are washed with sterile PBS and immediately transferred to the MTT assay (see below) used to evaluate the cell viability of the constructs. The assay meets the acceptance criteria if the ET-50 or 50% viability decreases within 4.77 - 8 hours for epidermal tissue and 12.2 < ET-50 < 37.5 minutes for EpiOcular tissue.

[0119] (IL-1α release) IL-1α is an important regulator of immune and inflammatory responses. In addition to the MTT assay, IL-1α is used to measure and predict the irritancy of substances tested using an epidermal model. Since IL-1α is released into the supernatant, samples from fresh and cryopreserved epidermal constructs are stored, and IL-1α is measured using an EIA assay.

[0120] The first vitrification protocol was developed for use with vein segments and rings. This process uses a 6-step (15-minute incubation) protocol to add a cryoprotectant (CPA) solution to the construct. Subsequently, the insert is placed into a glass scintillation vial, and 1.5 mL of vitrification solution and 0.3 mL of solution are placed inside the insert. The vial is rapidly cooled to -100 °C and then slowly cooled to -135 °C and stored until rewarming. During rewarming, the sample is slowly warmed to -100 °C and then rapidly warmed to room temperature. The vitrification solution is removed using 7 consecutive removal steps of 15 minutes each (Figure 4, original protocol). Several modifications were made to this protocol to obtain a better and more sustainable engraftment rate of epidermal constructs. Some of these modifications are shown in Table 1.

[0121]

Table 1

[0122] The simplest adjustment was a change to different vitrification solutions, VS55–VS70, for the vessels, with different contents of the same components: dimethyl sulfoxide (DMSO), propanediol (PD) and formamide (FD) (Figure 4, modified protocol).

[0123] We made a series of modifications to the method of injection and removal of vitrification solution from the constructs. These modifications included a shortened incubation step (5 min instead of 15 min), the use of a lower concentration of cryoprotectant to inject the highest strength vitrification solution into the constructs, and a more mechanical modification involving dilution of the highest strength vitrification solution to half the concentration by a simple dilution step as opposed to removal from one solution to the next. This reduced the time the constructs were exposed to the highest strength vitrification solution and reduced potential cytotoxicity from exposure to the vitrification solution (modified protocol). Finally, the addition of the antioxidant α-tocopherol (αT) and the caspase inhibitor Q-VD-OPH (QVD) to the culture medium of the constructs before and after vitrification improved viability and also the maintenance of viability for several days after rewarming (Figure 1, additives added).

[0124] Other additives were tried, but only QVD and αT showed significant improvement.

[0125] The arrived protocol begins with an overnight incubation with αT and QVD. The next day, constructs are vitrified using a 6-step addition protocol of 5 min each step to add cryoprotectant (CPA) solution to the constructs. The inserts are then left in the final vitrification solution containing 0.3 mL of solution within the insert. The vials are rapidly cooled to -100 °C, then slowly cooled to -135 °C, and stored until rewarming. During rewarming, samples are slowly warmed to -100 °C, then rapidly warmed to room temperature. The vitrification solution is removed through 7 successive removal steps of 5 min each. The first removal step dilutes the final vitrification solution to 50% of the final concentration. Constructs are left in media + additives for at least 24 h after rewarming to promote viability for at least 2-3 days after rewarming.

[0126] Having established a more suitable protocol for these 3D constructs, further exploration of the optimal vitrification solution was undertaken. Although some issues related to sustained viability of the constructs were overcome, further improvement of viability over several days in culture after rewarming was required.

[0127] Cytotoxicity was a major concern because the vitrification solutions have high cryoprotectant concentrations and the constructs are exposed to these compounds for extended periods of time during the injection / removal steps. A strategy was further pursued to use lower cryoprotectant concentrations in the injection / removal steps while the vitrification solutions are highly concentrated (i.e., inject / remove with VS55 but vitrify constructs with VS70). In this way, the constructs were exposed to a lower cryoprotectant concentration overall for extended periods of time and only briefly exposed to the full concentration of solution during vitrification. A series of vitrification solutions with several variations in injection / removal strategies were evaluated (see Table 2).

[0128] [Table 2]

[0129] This strategy was highly effective, with good survival rates immediately after rewarming, but with survival rates persisting up to 2 days after rewarming. The solution combinations that provided the highest survival rates are shaded in Table 2 (top).

[0130] Further testing of the epidermal constructs showed that the vitrified constructs responded similarly to the fresh controls when subjected to toxicity testing with Triton-X 100. The results are shown in FIG. 5.

[0131] Viability, measured using the MTT assay, showed similar viability of vitrified and fresh epidermal constructs exposed to Triton-X100 for up to 12.5 hours. Additional tests were performed to evaluate the release of IL-1α compared to fresh controls. Several vitrification solutions were tested (see samples marked with * in Table 2), and the release of IL-1α seemed to be somewhat dependent on the injection / removal combination of the vitrification solution used. Overall, the release was comparable to fresh constructs cultured for similar periods (see results in Table 3).

[0132] [Table 3]

[0133] Initial experiments were performed using glass vials, but further experiments were performed using the deep well plates of the present disclosure (Table 2). This allowed for the vitrification of multiple constructs at once. In the first experiments, 4-6 constructs were vitrified per plate. Further experiments were then performed (repeatedly, several times) where 24 constructs could be vitrified at once with good results showing consistent viability across plates.

[0134] In addition, several other constructs were also vitrified in glass vials and deep well plates, including not only the epidermis, but also EpiAirway, EpiOcular, and EpiCorneal, among others. All of these constructs responded well to vitrification and maintained viability for several days after rewarming. The results are shown in Figure 6.

[0135] Although constructs have been successfully vitrified in glass vials, more consistent viability has been observed when vitrified in the deep well plates of the present disclosure, however, timing is important when using deep well plates to ensure that constructs do not remain in full strength vitrification solution for long periods of time.

[0136] Additional experiments were performed to confirm the ability to vitrify several constructs at or above -135°C for up to 7 months using deep well plates, with results shown in Figure 7 (Epidermal 6 months, EpiAirway 7 months, EpiOcular 2 months). Various compositions (Epidermal 6 months, EpiAirway 7 months, EpiOcular 2 months).

[0137] Each construct showed good viability immediately after rewarming (>85%) and sustained viability for several days (>70%). Initial viability immediately after rewarming using glass vials was similar, but sustained viability several days after rewarming was inconsistent and poor, at approximately 45%.

[0138] In order to vitrify multiple constructs at once without worrying about the constructs remaining in the vitrification solution too long and affecting their viability, we designed a cassette to hold up to 24 constructs at a time so that the vitrification step could be performed on multiple constructs at once. Epidermal constructs were vitrified in deep-well plates or cassettes. After rewarming, metabolic activity was measured. We observed that constructs vitrified using cassettes showed comparable viability to constructs vitrified in deep-well plates. The results are shown in Figure 8.

[0139] All publications and patents cited throughout this disclosure are incorporated by reference in their entirety. While the foregoing description is described herein with reference to particular means, materials, and embodiments, it is not intended to be limited to the particulars disclosed herein, but rather to all functionally equivalent structures, methods, and uses, as fall within the scope of the appended claims. Furthermore, while only a few exemplary embodiments have been described in detail above, one skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without substantially departing from the disclosure of "Natural and Living Tissue Preservation and Methods of Preservation and Transport". Accordingly, all such modifications are intended to be included within the scope of this disclosure, as defined in the following claims. In the claims, means-plus-function phrases are intended to cover the structures described herein as performing the recited functions, and are intended to cover equivalent structures as well as structural equivalents. Thus, although nails and screws may not be structurally equivalent in that nails use cylindrical surfaces to fasten wooden parts, whereas screws use helical surfaces, in the context of fastening wooden parts, nails and screws may be equivalent structures. It is Applicant's express intent not to invoke 35 U.S.C. 112(f) to limit the claims herein, except to those claims which expressly use the word "means for" in conjunction with the relevant function.

Claims

1. 1. A method for preserving at least one biotechnological construct or natural tissue sample, comprising: (i) immersing said at least one bioengineered construct or natural tissue sample in a series of solutions with increasing concentrations of cryoprotectant to form at least one first bioengineered construct or natural tissue immersed in a final solution having a cryoprotectant concentration of 70% by weight or less; (ii) cooling the at least one first bioengineered construct or natural tissue in the final solution having a cryoprotectant concentration of 70% by weight or less to a temperature below the glass transition temperature of the final solution having a cryoprotectant concentration of 70% by weight or less; and (iii) immersing said at least one first bioengineered construct or natural tissue in a series of solutions with decreasing concentrations of said cryoprotectant to obtain at least one second bioengineered construct or natural tissue immersed in a solution substantially free of cryoprotectant, said at least one second bioengineered construct or natural tissue being substantially free of cryoprotectant; A method comprising:

2. 2. The method of claim 1, wherein prior to forming the at least one first bioengineered construct or natural tissue, the method further comprises the step of immersing the at least one first bioengineered construct or natural tissue in a pre-freezing solution containing at least one agent for at least 6 hours, wherein the agent is selected from the group consisting of an antioxidant and a caspase inhibitor.

3. 2. The method of claim 1, wherein in step (i), immersing said at least one bioengineered construct or natural tissue sample in 1 to 6 different solutions; or The series of solutions with decreasing concentrations of cryoprotectant may be obtained via a linear or non-linear concentration gradient.

4. 4. The method of claim 3, wherein the at least one bioengineered construct or natural tissue sample is immersed in 1 to 6 different solutions, and the at least one bioengineered construct or natural tissue sample is immersed in each of the different solutions for 5 minutes or less.

5. 2. The method of claim 1, wherein in step (iii), immersing said at least one first bioengineered construct or natural tissue sample in 1 to 7 different solutions; or The series of solutions with increasing concentrations of cryoprotectant may be obtained via a linear or non-linear concentration gradient.

6. 6. The method of claim 5, wherein the at least one first bioengineered construct or natural tissue sample is immersed in 1 to 7 different solutions, and the at least one first bioengineered construct or natural tissue sample is immersed in each of the different solutions for 5 minutes or less.

7. 2. The method of claim 1, wherein the cryoprotectant in step (ii) comprises at least one molecule selected from the group consisting of acetamide, cyclohexanediol, formamide, dimethylsulfoxide, ethylene glycol, polyethylene glycol, glycerol, a disaccharide, and a propanediol.

8. 2. The method of claim 1, wherein in step (i), each solution of the series of solutions in which the at least one bioengineered construct or natural tissue sample is immersed comprises at least one sugar.

9. 9. The method of claim 8, wherein the at least one sugar comprises sucrose.

10. The method of claim 2, wherein the agent comprises α-tocopherol.

11. The method of claim 2, wherein the agent comprises Q-VD-OPH.

12. 2. The method of claim 1, wherein step (i) is carried out in a manner that avoids ice growth during cooling, such that no ice damage occurs during the entire method for preserving the at least one bioengineered construct or native tissue sample.

13. 15. The method of claim 14, wherein the cryoprotectant concentration in the final solution of step (ii) is in the range of 8.0 to 11.0 M.

14. The method of claim 1 , wherein the at least one first bioengineered construct or natural tissue sample is obtained from an artificial tissue or organ.

15. 2. The method of claim 1, wherein the at least one first bioengineered construct or natural tissue sample is obtained from a cellular material selected from the group consisting of a mammalian organ and a mammalian tissue.

16. 6. The method of claim 5, wherein the cellular material is selected from the group consisting of human organs and human tissues.

17. The method of claim 1 , wherein the at least one first bioengineered construct or natural tissue sample is an epidermal construct.

18. 2. The method of claim 1, wherein the percent cell viability of the at least one second bioengineered construct or native tissue sample following completion of step (iii) is maintained at a level of at least 60% for at least 48 hours.

19. 2. The method of claim 1, wherein the percent cell viability of the at least one second bioengineered construct or native tissue sample after completion of step (iii) is maintained at a level of at least 70% for at least 48 hours.

20. 2. The method of claim 1, wherein the percent cell viability of the at least one second bioengineered construct or native tissue sample following completion of step (iii) is maintained at a level of at least 80% for at least 48 hours.

21. 3. The method of claim 2, wherein the at least one bioengineered construct or natural tissue sample is contained in a cassette that holds 6-384 constructs at a time, and the cassette containing the at least one first bioengineered construct or natural tissue sample is immersed in the pre-freezing medium.

22. 2. The method of claim 1, wherein in step (i) the at least one bioengineered construct or natural tissue sample is contained in a cassette holding between 6 and 384 constructs at a time, and the cassette containing the at least one bioengineered construct or natural tissue sample is immersed in each solution of the series of solutions of step (i).

23. 2. The method of claim 1, wherein in step (iii) the at least one first bioengineered construct or natural tissue sample is contained in a cassette holding 6-384 constructs at a time, and the cassette containing the at least one first bioengineered construct or natural tissue sample is immersed in each solution of the series of solutions of step (iii).

Citation Information

Patent Citations

  • In situ growth, freezing, and testing of cultured cells

    JP2003531595A

  • Cell freezing methods

    JP2014502610A

  • High subzero cryopreservation

    US20200154697A1

  • Ice-free vitrification and NANO warming of large tissue samples

    US20210137099A1

  • Method for ice-free cryopreservation of tissue

    WO2010096821A2